ReviewIntensive care medicine experimental2026
Mouse models to study von Willebrand factor in inflammation: a scoping review.
Review in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundVWF is released from activated endothelial cells and activated platelets in response to vascular injury, and is now recognized as an important contributor to a growing number of inflammatory conditions. This scoping review aims to identify and evaluate mouse models that have been used to study von Willebrand Factor (VWF) in the context of inflammation. Understanding the role of VWF in these models is crucial for selecting appropriate models and developing effective targeted treatments.
methodsA comprehensive literature search was conducted to identify studies using mouse models of inflammation from inception to October 2024. Two reviewers independently screened and extracted data on inflammation model methodology, organ outcomes, histological analyses, and biochemical changes if they pertain directly to VWF, or indirectly through ADAMTS13.
results150 studies published between 2000 and 2024 met inclusion criteria; 25% utilized C57BL/6 mice, and 43% used only male mice. Most (63%) studies used acute inflammation models, and 56 (37%) studies induced inflammation chemically in mice. Most studies (75%) reported an increase in VWF antigen levels, while only 31% of studies reported an increase in VWF activity. Few studies (33%) have also highlighted the therapeutic potential of ADAMTS13 to significantly reduce inflammation.
conclusionsThere is variability in the methods and outcomes in mouse models of inflammation. Future studies should consider the impact of methodology on VWF-related outcomes when using these models to study VWF-related processes and therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.